Eupraxia Pharmaceuticals Inc.
EPRXFOTCHealthcare
$3.04
$-0.20(-6.17%)
Market Cap$108291792
P/E Ratio—
52W High$6.7764
52W Low$2.9341
Eupraxia Pharmaceuticals Inc. (EPRXF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EPRXF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: Apr 1, 2024EPS Actual
-$0.21
Est. -$0.18 · -15.0%
Revenue
—
Fiscal Period
Q2 FY2024
FY ends December
Report Date
Apr 1, 2024
After Market Close
▼ Miss EPS
EPRXF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2024 | Apr 1, 2024 | -$0.18 | -$0.21 | -15.0% | — | — | — |
| ▲ Q1 FY2024 | Mar 28, 2024 | -$0.18 | -$0.12 | +35.7% | — | — | — |
| ▼ Q4 FY2023 | Nov 14, 2023 | -$0.11 | -$0.18 | -65.4% | — | — | — |
| ▲ Q3 FY2023 | Aug 11, 2023 | -$0.27 | -$0.27 | +1.1% | — | — | — |
| — Q2 FY2023 | May 11, 2023 | -$0.17 | -$0.17 | +0.7% | — | — | — |
| ▲ Q1 FY2023 | Mar 23, 2023 | -$0.43 | -$0.41 | +4.7% | — | $0.01B | — |
| ▲ Q4 FY2022 | Nov 7, 2022 | -$0.31 | -$0.16 | +48.9% | — | — | — |
| ▲ Q3 FY2022 | Aug 12, 2022 | -$0.30 | -$0.24 | +19.5% | — | — | — |
Q2 FY2024
Apr 1, 2024Miss
EPS Actual
-$0.21
EPS Est.
-$0.18
EPS Surpr.
-15.0%
Revenue
—
Q1 FY2024
Mar 28, 2024Beat
EPS Actual
-$0.12
EPS Est.
-$0.18
EPS Surpr.
+35.7%
Revenue
—
Q4 FY2023
Nov 14, 2023Miss
EPS Actual
-$0.18
EPS Est.
-$0.11
EPS Surpr.
-65.4%
Revenue
—
Q3 FY2023
Aug 11, 2023Beat
EPS Actual
-$0.27
EPS Est.
-$0.27
EPS Surpr.
+1.1%
Revenue
—
Q2 FY2023
May 11, 2023
EPS Actual
-$0.17
EPS Est.
-$0.17
EPS Surpr.
+0.7%
Revenue
—
Q1 FY2023
Mar 23, 2023Beat
EPS Actual
-$0.41
EPS Est.
-$0.43
EPS Surpr.
+4.7%
Revenue
—
Q4 FY2022
Nov 7, 2022Beat
EPS Actual
-$0.16
EPS Est.
-$0.31
EPS Surpr.
+48.9%
Revenue
—
Q3 FY2022
Aug 12, 2022Beat
EPS Actual
-$0.24
EPS Est.
-$0.30
EPS Surpr.
+19.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q3 FY2024 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q2 FY2024 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q1 FY2024 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q4 FY2022 | $-0.17 | $-0.17 | $-0.17 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2022 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2024 | Apr 1, 2024 | -15.0% | $3.24 | $3.04 | -6.17% |
| ▲ Q1 FY2024 | Mar 28, 2024 | +35.7% | $3.17 | $3.24 | +2.21% |
| ▼ Q4 FY2023 | Nov 14, 2023 | -65.4% | $3.96 | $3.96 | +0.00% |
| ▲ Q3 FY2023 | Aug 11, 2023 | +1.1% | $5.52 | $5.61 | +1.63% |
| ▲ Q2 FY2023 | May 11, 2023 | +0.7% | $4.35 | $4.35 | +0.00% |
| ▲ Q1 FY2023 | Mar 23, 2023 | +4.7% | $2.94 | $2.94 | +0.00% |
| ▲ Q4 FY2022 | Nov 7, 2022 | +48.9% | $3.31 | $3.31 | +0.00% |
| ▲ Q3 FY2022 | Aug 12, 2022 | +19.5% | $0.85 | $0.85 | +0.00% |
Q2 FY2024-6.17%
Report Date
Apr 1, 2024
EPS Beat/Miss
-15.0%
Price Before
$3.24
Price After
$3.04
Q1 FY2024+2.21%
Report Date
Mar 28, 2024
EPS Beat/Miss
+35.7%
Price Before
$3.17
Price After
$3.24
Q4 FY2023+0.00%
Report Date
Nov 14, 2023
EPS Beat/Miss
-65.4%
Price Before
$3.96
Price After
$3.96
Q3 FY2023+1.63%
Report Date
Aug 11, 2023
EPS Beat/Miss
+1.1%
Price Before
$5.52
Price After
$5.61
Q2 FY2023+0.00%
Report Date
May 11, 2023
EPS Beat/Miss
+0.7%
Price Before
$4.35
Price After
$4.35
Q1 FY2023+0.00%
Report Date
Mar 23, 2023
EPS Beat/Miss
+4.7%
Price Before
$2.94
Price After
$2.94
Q4 FY2022+0.00%
Report Date
Nov 7, 2022
EPS Beat/Miss
+48.9%
Price Before
$3.31
Price After
$3.31
Q3 FY2022+0.00%
Report Date
Aug 12, 2022
EPS Beat/Miss
+19.5%
Price Before
$0.85
Price After
$0.85
Avg Beat Reaction+0.64%
Avg Miss Reaction-3.08%
Beat Rate6 / 8 quarters
Largest Move-6.17% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EPRXF ends December
Eupraxia Pharmaceuticals Inc. (EPRXF) most recently reported earnings on April 1, 2024 for Q2 FY2024, posting EPS of $-0.21 — missing the analyst consensus of $-0.18 by -15.0%. The next EPRXF earnings date is expected around September 1, 2026.
Each quarter, investors track EPRXF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EPRXF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EPRXF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EPRXF earnings · 5 questionsEupraxia Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. EPRXF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EPRXF historically reports after market close (AMC).
EPRXF earnings datewhen is EPRXF earningsEPRXF next earnings datewhen does EPRXF report earningsEPRXF earnings calendar
▸ Source: FMP · Eupraxia Pharmaceuticals Inc. SEC filings · US GAAP · Eupraxia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026